SecBot SecBot

CNTB

Connect Biopharma Holdings Ltd
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001835268 Biotech & Drug Discovery
$0.8151 −0.03 (−3.99%)
Oct 27 4:00 PM ET · prev $0.8490
Market cap
$48.3M
Nano cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 10
in 14 days · EPS est. −$0.26
1 year
−49.1%
from $1.60 · Oct 27
30 days
−24.5%
from $1.08
52-week range
$0.7620–3.69
−78% from high · low Oct 22
Avg volume 20D
9.87M
Sep 30 spike 165.63M
Short interest
🔒 Subscribers only
Insider net
+$4.0M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/4 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Connect Biopharma announced overwhelmingly positive Phase 2 topline data for rademikibart in acute COPD…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $4.0M at an average $3.45. No open-market sales. Price is 76% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 8 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.277 → −$0.258 over 90 days. 1 up, 1 down in 30 days.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $0.7620 on Oct 22.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 4.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED335,642$798.8K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED257,454$612.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM102,148$243.1K
RENAISSANCE TECHNOLOGIES LLCTRIM87,300$207.8K
UBS Group AGDOUBLED66,451$158.2K
MILLENNIUM MANAGEMENT LLCNEAR_EXIT43,708$104.0K
BANK OF AMERICA CORP /DE/DOUBLED40,920$97.4K
JPMORGAN CHASE & CODOUBLED11,718$27.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy5Buy8Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Oct 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 30, 2026BTIG
MAINTAIN
MAINTAINBuy
Sep 22, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Sep 17, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 16, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$4.0M
bought · 1 insider
$0
sold · 0 insiders
−76.4%
vs their $3.45 cost
DateInsiderTypeValue
Sep 30, 2026
Xanthopoulos Kleanthis Gabriel
Director
AWARD5,000 sh
Sep 30, 2026
LIU JEAN I
Director
AWARD8,984 sh
Jun 30, 2026
Xanthopoulos Kleanthis Gabriel
Director
AWARD3,738 sh
Jun 30, 2026
LIU JEAN I
Director
AWARD6,718 sh
Mar 31, 2026
Xanthopoulos Kleanthis Gabriel
Director
AWARD2,816 sh
Mar 31, 2026
LIU JEAN I
Director
AWARD5,061 sh
Mar 31, 2026
Huang James
Director
BUY$4.0M

Earnings setup

Estimates
Nov 10
reports in 14 days
−$0.26
EPS estimate, this quarter
+7%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.26-$0.32–-$0.19+0.8%$4.5M
Next Q-$0.15-$0.29–$0.10+9.5%$23.1M
Current FY-$0.98-$1.22–-$0.72+2.6%$50.3M
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
r/pennystocks Bullish 23d ago
Anyone tracking CNTB?
1 upvotes · 6 comments
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Clinical trial readout
Results Pending: Matching placebo in prefilled syringe (Phase 2) — Completed 78d ago
Trial: Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) Sponsor: Co
Oct 6, 2026 SEC
BML Investment Partners, L.P. disclosed a 6.1% passive stake in Connect Biopharma Holdings Ltd via Schedule 13G…
SC 13G — Impact 3/10
Sep 30, 2026 SEC
Connect Biopharma announced overwhelmingly positive Phase 2 topline data for rademikibart in acute COPD exacerbations…
8-K — Impact 7/10
Sep 30, 2026 Press
Connect Biopharma reported highly positive Phase 2 topline results for rademikibart in COPD acute exacerbations…
Impact 7/10
Sep 30, 2026 Insider
Xanthopoulos Kleanthis Gabriel was granted 5,000 shares
Director
Sep 30, 2026 Insider
LIU JEAN I was granted 8,984 shares
Director
Sep 15, 2026 SEC
Connect Biopharma reported positive preliminary Phase 2 topline data for rademikibart as an add-on treatment for acute…
8-K — Impact 6/10
Jun 30, 2026 Insider
Xanthopoulos Kleanthis Gabriel was granted 3,738 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
CNTB Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 16, 2026
Trial readout
Results Pending: Matching placebo in prefilled syringe (Phase 2) — Completed 78d ago
Trial: Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) Sponsor: Connect Biopharm LLC Phase: Phase 2 | Completed…
Sep 30, 2026
FDA
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Sep 30, 2026
Short interest
Short Interest: CNTB up 26% to 3.5M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈5.56% of shares outstanding (est.)
Sep 16, 2026
Trial readout
Results Pending: Matching placebo in prefilled syringe (Phase 2) — Completed 48d ago
Trial: Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) Sponsor: Connect Biopharm LLC Phase: Phase 2 | Completed…
Sep 16, 2026
Trial readout
Results Pending: Matching placebo in prefilled syringe (Phase 2) — Completed 61d ago
Trial: Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Sponsor: Connect Biopharm LLC Phase: Phase 2 |…

SecBot reports

7 filings · 2 press releases · 2 bullish · 1 bearish · 2 mixed · 2 neutral
All CNTB filing & press-release reports (9)